

## CLAIMS

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (original): 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.

Claim 2 (previously presented): 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate hemihydrate in crystalline form, having a melting point of  $T_{m.p.} = 305 \pm 5^{\circ}\text{C}$  (determined by DSC; evaluation using peak-maximum; heating rate:  $10^{\circ}\text{C}/\text{min}$ ).

Claim 3 (previously presented): Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate hemihydrate according to claim 2, the X-ray powder diagram of which includes, *inter alia*, the characteristic values  $d = 5.43 \text{ \AA}$ ,  $5.08 \text{ \AA}$ ,  $4.71 \text{ \AA}$ ,  $4.50 \text{ \AA}$  and  $4.43 \text{ \AA}$  with an intensity of more than 40%.

Claim 4 (previously presented): Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate hemihydrate according to claim 2, characterised by a unit cell determined by X-ray powder diffractometric measurements having the following dimensions:

a = 16.332 Å,  
b = 19.199 Å,  
c = 11.503 Å,  
 $\alpha$  = 95.27°,  
 $\beta$  = 90.13°,  
 $\gamma$  = 110.83° and  
V = 3354.4 Å<sup>3</sup>

Claim 5 (cancelled)

Claim 6 (original): A pharmaceutical composition comprising 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and one or more inert carriers and/or diluents.

Claim 7 (cancelled)

Claim 8 (original): A prodrug of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.

Claim 9 (cancelled)

Claim 10 (cancelled)

Application No. 10/623,971  
Amendment dated May 26, 2006  
Reply to Office action of March 2, 2006

Claim 11 (previously presented): 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate hemihydrate in crystalline form.